EXOZ Earnings

EXOZ reported its earnings on 2025-05-12, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.22, surpassing the expected 0 by 0% . The stock experienced a 16.03% price change on the earnings day and a 19.94% change over the next five days, reflecting market reactions to the results.

Following EXOZ's earnings announcement on 2025-05-12, the stock price moved by 16.03% on the day of the release. Over the subsequent five days, it saw a 19.94% change. Historically, EXOZ's stock price tends to shift by an average of -10.61% in the 10 days leading up to earnings and +11.56% in the 10 days following, providing insight into potential market.

For , analysts estimate EXOZ’s annual revenue to reach undefined, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue Go Down by -31.38% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between EXOZ's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for were Go Down by -31.38%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EXOZ's stock price typically moves by -10.61% in the 10 days before its earnings and +11.56% in the 10 days after. For the upcoming earnings, analysts expect an EPS of undefined and revenue of undefined.

The earnings call summary indicates a mixed sentiment. While there are opportunities in the medical field and potential partnerships, there are also significant risks, such as regulatory issues and supply chain challenges. The Q&A reveals optimism about NCT's market potential, but management's lack of specific guidance and clarity on future products tempers expectations. Additionally, the financials show increased expenses without a change in cash reserves, suggesting limited growth. These factors, combined with the competitive pressures and economic uncertainties, suggest a neutral impact on stock price.